Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.950
+0.060 (3.17%)
Nov 28, 2025, 4:00 PM EST - Market closed
Innate Pharma Revenue
Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.
Revenue (ttm)
12.64M EUR
Revenue Growth
-62.60%
P/S Ratio
12.30
Revenue / Employee
69,812 EUR
Employees
181
Market Cap
182.58M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IPHA News
- 15 hours ago - Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 - Business Wire
- 11 days ago - Innate Pharma to Present at Jefferies Global Healthcare Conference - Business Wire
- 14 days ago - Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire
- 18 days ago - Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Business Wire
- 23 days ago - Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates - Business Wire
- 4 weeks ago - Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript - Seeking Alpha
- 6 weeks ago - Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 - Business Wire